EA 4391, université Paris-Est, Créteil, France; Service de neurologie, groupe hospitalier Henri-Mondor, AP-HP, Créteil, France.
Neurophysiol Clin. 2013 Dec;43(5-6):303-12. doi: 10.1016/j.neucli.2013.09.004. Epub 2013 Oct 26.
To evaluate the concept that iron depletion (ID) induced by bloodletting and followed by recombinant human erythropoietin (rhEPO) administration could be a therapeutic strategy in progressive multiple sclerosis (PMS) and that it could be assessed by neurophysiological measurements.
In four patients with PMS, bloodletting was performed until ID was induced, and then rhEPO was administered (300 UI/kg/week). The changes induced by the treatment were assessed by clinical scores, biological tests, and neurophysiological study of cortical excitability using transcranial magnetic stimulation techniques.
The treatment was well tolerated except for muscle cramps and one popliteal vein thrombosis in a patient confined to chair. ID was obtained within 28 weeks and was associated with endogenous production of EPO. No bloodletting was further required during a six-month period after introduction of rhEPO. At the end of the follow-up (up to one year), fatigue and walking capacities tended to improve in two patients. Neurophysiological changes were characterized by an increased cortical excitability, including a decrease of motor thresholds and an enhancement of intracortical facilitation and cerebellothalamocortical inhibition.
The combined ID-rhEPO therapy could authorize a prolonged administration of rhEPO in PMS patients, able to modify cortical excitability of the glutamatergic and gabaergic circuits. These preliminary data are encouraging to design a larger, controlled therapeutical trial to assess the value of such a strategy to improve functional symptoms in PMS patients, and maybe to prevent axonal degeneration. Neurophysiological measurements based on cortical excitability studies could provide sensitive parameters to evaluate treatment-induced changes in this context.
评估放血诱导铁耗竭(ID),随后给予重组人红细胞生成素(rhEPO)治疗,这一策略是否可用于进展性多发性硬化(PMS),并通过神经生理测量进行评估。
在 4 名 PMS 患者中,进行放血直至 ID 被诱导,然后给予 rhEPO(300 UI/kg/周)。通过临床评分、生物测试和经颅磁刺激技术评估皮质兴奋性的神经生理研究来评估治疗引起的变化。
除一名患者因肌肉痉挛和腓静脉血栓形成而限制在椅子上外,该治疗耐受良好。在 28 周内获得 ID,并与内源性 EPO 产生相关。在 rhEPO 引入后的 6 个月内无需进一步放血。在随访结束时(长达一年),两名患者的疲劳和行走能力均有改善趋势。神经生理变化的特征是皮质兴奋性增加,包括运动阈值降低以及皮质内易化和小脑丘脑皮质抑制增强。
联合 ID-rhEPO 治疗可授权 PMS 患者延长 rhEPO 治疗,从而改变谷氨酸能和 GABA 能回路的皮质兴奋性。这些初步数据令人鼓舞,可设计更大规模的对照治疗试验,以评估这种策略改善 PMS 患者功能症状的价值,并可能预防轴突变性。基于皮质兴奋性研究的神经生理测量可能为评估该治疗方法在此背景下引起的变化提供敏感参数。